InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Litton Mark James, Chairman & CEO. Insider active across 2 companies, notably Athira Pharma, Inc.. In total, 13 disclosures have been logged. Breakdown: 0 buy · 2 sells. History available since 18 May 2021. The latest transaction was filed on 31 December 2024 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations13 total
108,333 shares0Common StockSEC:0001415889-25-000536:0
20,000 shares0Common StockSEC:0001415889-24-022983:0
20,000 shares0Common StockSEC:0001415889-24-004153:0
20,000 shares0Common StockSEC:0001209191-24-001150:0
662 shares@ US$2.743.7% of flowCommon StockSEC:0001209191-23-005818:0
757 shares@ US$7.0611.3% of flowCommon StockSEC:0001209191-22-039340:0
885 shares@ US$12.5121.7% of flowCommon StockSEC:0001209191-22-005628:0
885 shares@ US$12.5120.8% of flowCommon StockSEC:0001209191-22-005628
867 shares@ US$14.4522.7% of flowCommon StockSEC:0001209191-21-052564:0
867 shares@ US$14.4521.8% of flowCommon StockSEC:0001209191-21-052564
25,000 sharesCommon StockSEC:0001209191-16-090205:0
17,291 sharesCommon StockSEC:0001209191-16-090205:1
7,709 sharesCommon StockSEC:0001209191-16-090205:2
13 of 13 declarations
About Litton Mark James
Litton Mark James is the Chairman & CEO of Athira Pharma, Inc. In this role, he is responsible for the strategic direction and management of the company's operations. His leadership is essential for guiding Athira Pharma, Inc. towards its innovation and growth objectives.
